Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitinė, lėtinė, b-ląstelė - antinavikiniai vaistai - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

edupharma, uab - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemija, mieloidas - antinavikiniai vaistai - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leukemija, mieloidas, ūmus - antinavikiniai vaistai - xospata yra nurodyta kaip monotherapy gydyti suaugusiems pacientams, kurie turi atsinaujino arba ugniai atsparios ūminės mieloidinės leukemijos (ppp) su flt3 mutacijos.